Possible treatment for working memory decline with age

September, 2011

A study has successfully countered reduced activity in the prefrontal cortex seen in older monkeys. Clinical trials are now investigating whether the drug can improve working memory in older humans.

A study comparing activity in the dorsolateral prefrontal cortex in young, middle-aged and aged macaque monkeys as they performed a spatial working memory task has found that while neurons of the young monkeys maintained a high rate of firing during the task, neurons in older animals showed slower firing rates. The decline began in middle age.

Neuron activity was recorded in a particular area of the dorsolateral prefrontal cortex that is most important for visuospatial working memory. Some neurons only fired when the cue was presented (28 CUE cells), but most were active during the delay period as well as the cue and response periods (273 DELAY neurons). Persistent firing during the delay period is of particular interest, as it is required to maintain information in working memory. Many DELAY neurons increased their activity when the preferred spatial location was being remembered.

While the activity of the CUE cells was unaffected by age, that of DELAY cells was significantly reduced. This was true both of spontaneous activity and task-related activity. Moreover, the reduction was greatest during the cue and delay periods for the preferred direction, meaning that the effect of age was to reduce the ability to distinguish preferred and non-preferred directions.

It appeared that the aging prefrontal cortex was accumulating excessive levels of an important signaling molecule called cAMP. When cAMP was inhibited or cAMP-sensitive ion channels were blocked, firing rates rose to more youthful levels. On the other hand, when cAMP was stimulated, aged neurons reduced their activity even more.

The findings are consistent with rat research that has found two of the agents used — guanfacine and Rp-cAMPS — can improve working memory in aged rats. Guanfacine is a medication that is already approved for treating hypertension in adults and prefrontal deficits in children. A clinical trial testing guanfacine's ability to improve working memory and executive functions in elderly subjects who do not have dementia is now taking place.

Reference: 

[2349] Wang, M., Gamo N. J., Yang Y., Jin L. E., Wang X-J., Laubach M., et al.
(2011).  Neuronal basis of age-related working memory decline.
Nature. advance online publication,

Related News

A study (“Midlife in the United States”) assessing 3,343 men and women aged 32-84 (mean age 56), of whom almost 40% had at least a 4-year college degree, has found evidence that frequent cognitive activity can counteract the detrimental effect of poor education on age-related cognitive decline.

Previous research has shown that older adults are more likely to incorrectly repeat an action in situations where a

It’s now well established that older brains tend to find it harder to filter out irrelevant information. But now a new study suggests that that isn’t all bad.

A study involving 155 women aged 65-75 has found that those who participated in resistance training once or twice weekly for a year significantly improved their selective attention (maintaining mental focus) and conflict resolution (as well as muscular function of course!), compared to those who

A number of rodent studies have shown that blueberries can improve aging memory; now for the first time, a human study provides evidence.

A study involving 57 cognitively healthy older adults has found that those who showed decreased memory performance two years later (20 of the 57) had higher baseline levels of phosphorylated tau231 in the

Midlife hypertension has been confirmed as a risk factor for the development of dementia in late life, but there have been conflicting findings about the role of late-life hypertension.

By following 597 Alzheimer’s patients over 15 years, researchers have determined that a simple progression rate can be calculated at the initial visit, using symptom onset and present performance, and that this can reliably identify slow, intermediate and rapid progression.

A survey of more than 100 studies involving PIB-PET, a diagnostic tool that involves injecting a radiotracer called

Pages

Subscribe to Latest newsSubscribe to Latest newsSubscribe to Latest health newsSubscribe to Latest news